Intersect ENT Inc (XENT) Issues Quarterly Earnings Results

The highest EPS estimate is ($0.14) and the lowest is ($0.21). After $-0.23 actual earnings per share reported by Intersect ENT Inc for the previous quarter, Wall Street now forecasts -8.70 % EPS growth. It now has negative earnings. They expect $0.65 EPS, up 1.56% or $0.01 from last year's $0.64 per share. It is down 79.98% since June 1, 2016 and is uptrending. The medical equipment provider reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. Intersect ENT had a negative return on equity of 21.25% and a negative net margin of 35.69%. The business had revenue of $20.47 million for the quarter, compared to analysts' expectations of $19.39 million.

A number of analysts have weighed in on XENT shares. Northland Securities reaffirmed a "buy" rating and issued a $17.00 target price on shares of Intersect ENT in a research report on Monday, March 13th. The original version of this article can be viewed at https://www.com-unik.info/2017/06/05/intersect-ent-inc-xent-rating-reiterated-by-william-blair-updated-updated.html. Zacks Investment Research lowered Intersect ENT from a "hold" rating to a "strong sell" rating in a research note on Saturday, April 15th. Northland Securities raised their price target on Intersect ENT from $17.00 to $22.00 and gave the stock an outperform rating in a research report on Thursday, May 4th. Deutsche Bank AG raised Intersect ENT from a "hold" rating to a "buy" rating and boosted their price target for the stock from $15.00 to $19.00 in a research report on Monday, March 6th. The company has an average rating of "Buy" and a consensus target price of $18.60. 502,992 shares of the company were exchanged. Canaccord Genuity restated a "buy" rating and issued a $16.00 price target on shares of Intersect ENT in a research report on Tuesday, February 21st. The company's 50 day moving average price is $21.92 and its 200 day moving average price is $15.47. The company has market cap of $6.40 billion.

Sectoral Asset Management Inc increased Intersect Ent Inc (XENT) stake by 218.15% reported in 2016Q4 SEC filing.

COPYRIGHT VIOLATION WARNING: This piece of content was published by BBNS and is owned by of BBNS.

The share price of Intersect ENT, Inc.

In other news, COO Richard E. Kaufman sold 20,000 shares of Intersect ENT stock in a transaction dated Monday, May 22nd. Following the transaction, the chief operating officer now owns 182,321 shares of the company's stock, valued at $4,169,681.27. Insiders have sold 81,250 shares of company stock worth $1,560,163 over the last three months. Teachers Advisors LLC now owns 59,774 shares of the medical equipment provider's stock valued at $723,000 after buying an additional 206 shares in the last quarter.

Several hedge funds have recently added to or reduced their stakes in XENT. State Street Corp increased its stake in Intersect ENT by 12.8% in the fourth quarter. Russell Investments Group Ltd. purchased a new stake in shares of Intersect ENT during the fourth quarter valued at approximately $377,000. Kopp Investment Advisors LLC now owns 357,795 shares of the medical equipment provider's stock valued at $4,329,000 after buying an additional 119,097 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of Intersect ENT by 129.4% in the third quarter. Wellington Management Group LLP now owns 2,921,012 shares of the medical equipment provider's stock valued at $50,095,000 after buying an additional 10,683 shares in the last quarter. Neuberger Berman Group LLC now owns 884,627 shares of the medical equipment provider's stock valued at $15,171,000 after buying an additional 293,949 shares during the last quarter.

Large investors have recently modified their holdings of the stock.

Intersect ENT, Inc.is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is created to allow ENT physicians to manage patient care.

Latest News